Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Bushra Sumra’s career highlights the profound impact that expertise in clinical research and regulatory compliance can have ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Over 400 enforcement actions, including show cause notices, production stoppages, and license cancellations, have been taken ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

African National regulatory agencies (NRAs) under the World Health Organisation’s (WHO) maturity level 3, have signed a ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

New Partnership for Africa’s Development (AUDA-NEPAD) and the Africa Centres for Disease Control and Prevention (Africa CDC) ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Alys Pharmaceuticals has received clearance from the US FDA and Health Canada for a Phase IIa trial of ALY-101 for alopaecia ...